Skip to main content
Erschienen in: Endocrine Pathology 2/2008

01.06.2008

Galectin-3 Expression in Tumor Progression and Metastasis of Papillary Thyroid Carcinoma

verfasst von: Hüseyin K. Türköz, Hülya Öksüz, Ziya Yurdakul, Deniz Özcan

Erschienen in: Endocrine Pathology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Galectin-3 plays important roles in cell adhesion, cell proliferation, apoptosis, neoplastic transformation, and metastasis. Galectin-3 expression has been evaluated in various malignant neoplasms to determine its effectiveness in differential diagnosis from benign lesions and its effects on carcinogenesis. There are few and somewhat controversial results regarding its changes through cancer progression in thyroid malignancies. We studied the presence of galectin-3 expression immunohistochemically and its relation with tumor invasiveness and lymph node metastasis in 89 cases of papillary carcinoma of the thyroid. Galectin overexpression was less frequent in cases with lymph node metastases compared with cases without lymph node metastasis (P = 0.001). Metastatic foci in lymph nodes showed a lower degree of galectin-3 overexpression than their primary lesions (P = 0.001). Degree of galectin-3 overexpression was also lower in larger tumors (P = 0.009). Additionally, a decreased level of galectin-3 overexpression was observed at the invasive edges of the tumors (P = 0.001). Galectin-3 overexpression is more profound in early stages of papillary carcinoma, and its expression intensity decreases during tumor progression. This finding is consistent with roles for galectin-3 in cell adhesion to other tumor cells and the matrix.
Literatur
1.
Zurück zum Zitat Wang JL, Werner EA, Laing JG, Patterson RJ. Nuclear and cytoplasmic localization of a lectin–ribonucleoprotein complex. Biochem Soc Trans 20(2):269–74, 1992.PubMed Wang JL, Werner EA, Laing JG, Patterson RJ. Nuclear and cytoplasmic localization of a lectin–ribonucleoprotein complex. Biochem Soc Trans 20(2):269–74, 1992.PubMed
2.
Zurück zum Zitat Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell–cell adhesion. Cancer Res 56(19):4530–4, 1996.PubMed Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell–cell adhesion. Cancer Res 56(19):4530–4, 1996.PubMed
5.
Zurück zum Zitat Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, Nomura T, et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 18(4):787–92, 2001.PubMed Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, Nomura T, et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 18(4):787–92, 2001.PubMed
6.
Zurück zum Zitat Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, Nakatani Y, et al. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 15(1):143–8, 1999.PubMed Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, Nakatani Y, et al. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 15(1):143–8, 1999.PubMed
7.
Zurück zum Zitat Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 9(2):305–28, 2004.PubMed Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 9(2):305–28, 2004.PubMed
8.
Zurück zum Zitat Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18(1):48–57, 2005. doi:10.1038/modpathol.3800235.PubMedCrossRef Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18(1):48–57, 2005. doi:10.​1038/​modpathol.​3800235.PubMedCrossRef
10.
Zurück zum Zitat DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. Lyon: IARC, pp. 50–66, 2004. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. Lyon: IARC, pp. 50–66, 2004.
11.
Zurück zum Zitat Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58(14):3015–20, 1998.PubMed Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58(14):3015–20, 1998.PubMed
12.
Zurück zum Zitat Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, Chapelle Ade L, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18(1):48–57, 2005. doi:10.1038/modpathol.3800235.PubMedCrossRef Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, Chapelle Ade L, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18(1):48–57, 2005. doi:10.​1038/​modpathol.​3800235.PubMedCrossRef
13.
Zurück zum Zitat Torres-Cabala C, Bibbo M, Panizo-Santos A, Barazi H, Krutzsch H, Roberts DD, et al. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol 50(5):518–28, 2006.PubMed Torres-Cabala C, Bibbo M, Panizo-Santos A, Barazi H, Krutzsch H, Roberts DD, et al. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol 50(5):518–28, 2006.PubMed
14.
Zurück zum Zitat Rossi ED, Raffaelli M, Mule’ A, Miraglia A, Lombardi CP, Vecchio FM, et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Acta Cytol 50(5):518–28, 2006. Rossi ED, Raffaelli M, Mule’ A, Miraglia A, Lombardi CP, Vecchio FM, et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Acta Cytol 50(5):518–28, 2006.
15.
Zurück zum Zitat Castronovo V, Campo E, van den Brule FA, Claysmith AP, Cioce V, Liu FT, et al. Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. J Natl Cancer Inst 84(15):1161–9, 1992. doi:10.1093/jnci/84.15.1161.PubMedCrossRef Castronovo V, Campo E, van den Brule FA, Claysmith AP, Cioce V, Liu FT, et al. Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. J Natl Cancer Inst 84(15):1161–9, 1992. doi:10.​1093/​jnci/​84.​15.​1161.PubMedCrossRef
17.
Zurück zum Zitat Idikio H. Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol 12(6):1287–90, 1998.PubMed Idikio H. Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol 12(6):1287–90, 1998.PubMed
19.
20.
Zurück zum Zitat Song YK, Billiar TR, Lee YJ. Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol 160(3):1069–75, 2002.PubMed Song YK, Billiar TR, Lee YJ. Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol 160(3):1069–75, 2002.PubMed
21.
Zurück zum Zitat Aratake Y, Nomura H, Kotani T, Marutsuka K, Kobayashi K, Kuma K, et al. Coexistent anaplastic and differentiated thyroid carcinoma. Am J Clin Pathol 125(3):399–406, 2006. doi:10.1309/LF3Q-1NQK-MT2N-9KNV. Aratake Y, Nomura H, Kotani T, Marutsuka K, Kobayashi K, Kuma K, et al. Coexistent anaplastic and differentiated thyroid carcinoma. Am J Clin Pathol 125(3):399–406, 2006. doi:10.​1309/​LF3Q-1NQK-MT2N-9KNV.
22.
Zurück zum Zitat Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 31(4):428–33, 2000. doi:10.1053/hp.2000.6534.PubMedCrossRef Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 31(4):428–33, 2000. doi:10.​1053/​hp.​2000.​6534.PubMedCrossRef
23.
Zurück zum Zitat Cvejic DS, Savin SB, Petrovic IM, Paunovic IR, Tatic SB, Havelka MJ. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size. Head Neck 27(12):1049–55, 2005. doi:10.1002/hed.20276.PubMedCrossRef Cvejic DS, Savin SB, Petrovic IM, Paunovic IR, Tatic SB, Havelka MJ. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size. Head Neck 27(12):1049–55, 2005. doi:10.​1002/​hed.​20276.PubMedCrossRef
Metadaten
Titel
Galectin-3 Expression in Tumor Progression and Metastasis of Papillary Thyroid Carcinoma
verfasst von
Hüseyin K. Türköz
Hülya Öksüz
Ziya Yurdakul
Deniz Özcan
Publikationsdatum
01.06.2008
Verlag
Humana Press Inc
Erschienen in
Endocrine Pathology / Ausgabe 2/2008
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-008-9033-3

Weitere Artikel der Ausgabe 2/2008

Endocrine Pathology 2/2008 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …